ArticleFrontiers in cellular and infection microbiology2025
Efficacy analysis of ultrashort wave therapy as adjunctive treatment for pediatric patients with macrolide-resistant Mycoplasma pneumoniae pneumonia.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of macrolide-resistant Mycoplasma pneumoniae pneumonia (MRMPP) has been increasing in children, resulting in prolonged illness and complications. This study aimed to evaluate the effect of ultrashort-wave therapy (USWT) as a second-line therapy in patients with MRMPP. Methods: This is a retrospective controlled practice clinical study of 112 children hospitalized with MRMPP, assigned to a control group (n = 75) who received standard therapy, or a USWT group (n = 37), who received standard therapy plus USWT. The groups were assigned based on parental preference, not randomization. The primary outcomes studied were length of stay, pulmonary lesion resolution, and new lesion rate; a secondary analysis investigated time to introduce USWT. Results: The baseline clinical characteristics were similar between the two groups, with the exception of the mean length of stay. The length of stay was significantly longer for the USWT group (10.9 ± 3.1 vs. 9.4 ± 2.4 days, p = 0.01). The resolution of lesions was significantly higher (97.3 vs. 72.0%, p < 0.01), and new lesion rates were lower in the USWT group (16.2 vs. 29.3%), but not significant (p = 0.20). The multivariate analysis confirmed that USWT and severity of pneumonia were significant independent variables affecting lung length of stay (p <0.01; p <0.001). Conclusions: USWT as adjunctive therapy for children with MRMPP significantly improved resolution of pulmonary lesions, while also being associated with longer length of stay. These findings suggest that USWT may be a supportive, non-pharmacologic adjunctive therapy to improve recovery from antibiotic-resistant pediatric pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.